Recurrent Bell's palsy
Recurrent Bell's palsy
复制标题
DOI：
10.1111/coa.13293
复制
发表时间：
2019-05-01
影响因子：
2.1
通讯作者：
Yeo, Seung Geun
中科院分区：
文献类型：
--
作者：
Dong, Sung Hwa;Jung, Ah Ra;Yeo, Seung Geun
目的复发性面瘫于1871年首次报道，但其病因、定义、分类、发病机制、治疗方案及预后尚未明确。目前还没有关于复发性贝尔氏麻痹的系统综述和荟萃分析。本研究的目的是通过系统回顾和荟萃分析来评估复发性贝尔麻痹的临床表现。使用检索词“复发性贝尔氏麻痹”和“复发性面瘫”检索SCOPUS、PubMed、Cochrane Library和EBSCO数据库，检索到2018年5月1日为止涉及复发性贝尔氏麻痹患者的研究。还审查了合格研究的参考文献清单。结果在这四个数据库中检索到222篇研究的题目和摘要；其中，分析了27项研究，涉及来自13个国家的1041名患者。贝尔氏麻痹复发患者的平均百分比从0.8%到19.4%不等。包括191例患者的5项研究被纳入meta分析。结论既往贝尔氏麻痹患者中，贝尔氏麻痹复发的平均发生率为6.5%。复发疾病的侧边，相对于原发疾病的侧边，对患者的预后没有影响。在所有贝尔麻痹患者中，66.0%的患者完全康复，复发患者的康复率低于原发性贝尔麻痹患者。
ObjectiveAlthough recurrent facial palsy was first reported in 1871, the aetiology, definitions, classifications, pathogenesis, treatment options and prognosis have not been clearly determined. There have been no systematic reviews and meta-analyses of recurrent Bell's palsy. The purpose of this study was to evaluate the clinical manifestations of recurrent Bell's palsy through a systematic review and meta-analysis.DesignThe SCOPUS, PubMed, Cochrane Library and EBSCO databases were searched through 1 May 2018, using the search terms recurrent Bell's palsy and recurrent facial palsy, for studies involving patients with recurrent Bell's palsy. Reference lists of eligible studies were also reviewed.ResultsA search of titles and abstracts in these four databases identified 222 studies; of these, 27 studies, involving 1041 patients from 13 countries, were analysed. The mean percentage of patients who experienced recurrence of Bell's palsy ranged from 0.8% to 19.4%. Five studies that included 191 patients were included in the meta-analysis.ConclusionsAmong patients previously affected by Bell's palsy, the mean incidence of recurrent Bell's palsy was 6.5%. Sidedness of recurrent disease, relative to the side of the original disease, had no effect on patient prognosis. Of all patients with Bell's palsy, 66.0% recovered completely, with the recovery rate lower in patients with recurrent than with primary Bell's palsy.